Day: December 8, 2025

EMERYVILLE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference. Members of the management team will also be available for one-on-one meetings. 44th Annual J.P. Morgan Healthcare ConferencePresentation Date: Wednesday, Jan 14, 2026Presentation Time: 7:30 a.m. PTWebcast Link: WebcastAn archived copy of the webcast will be available for up to one year on the “Investors” section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/events. About 4DMT          4DMT is a leading...

MIAMI, Dec. 08, 2025 (GLOBE NEWSWIRE) — SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that the Company will give several oral presentations at the 2nd Asian Conference on Innovative Therapies for Diabetes Management (ATTD-Asia) being held December 9-11, 2025, in Singapore. Data to be presented will highlight the progress of SAB BIO’s lead program, SAB-142, a potentially best-in-class, disease-modifying, redosable immunotherapy in clinical development for delaying the progression of T1D in new-onset, Stage 3 patients, including:Phase 1 study data showcasing the clinically validated, multi-specific mechanism of action of SAB-142. Phase 1 study data demonstrating immunomodulation...

San Diego, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) — California Bancorp (the “Company”) (Nasdaq: BCAL), the holding company for California Bank of Commerce, N.A. (the “Bank”), announces that its Board of Directors has approved the Company’s first quarterly cash dividend. This strategic decision reflects the Company’s strong financial performance and commitment to creating shareholder value.  The Company will pay a cash dividend of $0.10 per share on January 15, 2026, payable to shareholders of record as of December 24, 2025.  “Initiating a dividend reflects the robust performance of our relationship-based banking franchise, exemplifies our dedication to creating shareholder value, and is a useful tool in managing our strong capital position,” said David Rainer, Executive Chairman of the Company and the Bank. ABOUT CALIFORNIA...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation  Placebo-adjusted mean weight loss up to 15.3% (35.5 lbs) observed with 240 mg dose in the exploratory ACCESS II study at 36 weeks No adverse event-related treatment discontinuations observed when starting at lower 2.5 mg dose in ACCESS Open Label Extension and Body Composition Study Data comprehensively support and inform advancement to Phase 3 clinical development program in mid-2026 Company to host conference call today at 8:30 a.m. Eastern Time SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) — Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases,...

ATLANTA, Dec. 08, 2025 (GLOBE NEWSWIRE) — Clip Money Inc. (TSX-V: CLIP) (OTCQB: CLPMF) (“Clip Money” or the “Company”), operator of North America’s only multi-bank cash deposit system for businesses with over 8,000 deposit accepting locations, is pleased to announce an expanded portfolio partnership with Centennial, a leading retail and mixed-use real estate operator with over 35 properties in the United States. Through this collaboration, more than a dozen Centennial locations will now host ClipDrops, a commercial cash deposit solution for use by Centennial tenants, providing over 1,600 retail and restaurant tenants with an onsite alternative to traditional bank deposits. This partnership marks a significant milestone in Clip’s mission to modernize and simplify cash-handling for retailers across North America. With the addition...

Rocket Doctor AI joins forces with the CAN Health Network to deliver an AI-powered Clinical Decision Support System (CDSS) in collaboration with Health Cities Alberta.Initial rollout will take place at up to four primary care sites serving up to 20 physicians, running from December 2025 to March 2026.The project aims to reduce intake time by 25–40% and improve diagnostic accuracy using Rocket Doctor AI’s proprietary Global Library of Medicine (GLM). Goal to eventually expand CDSS province-wide across AlbertaVancouver, BC, Dec. 08, 2025 (GLOBE NEWSWIRE) — Rocket Doctor AI Inc. (CSE: AIDR, OTC: AIRDF, Frankfurt: 939) (“Rocket Doctor AI”) today announced a new partnership with the CAN Health Network to test its AI-powered Clinical Decision Support System (CDSS) in collaboration with Health Cities. The project will launch...

SINGAPORE, Dec. 08, 2025 (GLOBE NEWSWIRE) — CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumors, today announced that it has entered into a Memorandum of Understanding with Universiti Malaya Medical Centre (“UMMC”) a teaching hospital under Universiti Malaya to establish a multi-site, first-in-human Phase I clinical trial to investigate the safety and efficacy of CytoMed’s patented allogeneic unmodified Gamma Delta (γδ) T cells (“CTM-GDT”) (without genetically modifying the cells to express any receptor) for no-option cancer patients in Malaysia. This...

Investigator-Initiated Preclinical studies at CIC biomaGUNE aimed at combatting Glioblastoma Multiforme  Research will evaluate effects of intra-arterial delivery of Annamycin HOUSTON, Dec. 08, 2025 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced it has entered into a research and material transfer agreement with CIC biomaGUNE, a non-profit research organization created to promote scientific research and technological innovation at the highest levels in the Basque Country, Spain, for investigator-initiated preclinical research evaluating Annamycin for the treatment of glioblastoma multiforme (GBM), a form of brain cancer. Under the terms of...